Drug Profile
Clervonafusp alfa - Valerion Therapeutics
Alternative Names: VAL-1221Latest Information Update: 11 Jul 2023
Price :
$50
*
At a glance
- Originator Valerion Therapeutics
- Developer Parasail; Valerion Therapeutics
- Class Recombinant fusion proteins
- Mechanism of Action Alpha glucosidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lafora disease
- Phase I/II Glycogen storage disease type II
Most Recent Events
- 05 Jul 2023 Clinical trials in Lafora disease (In adolescents, In adults) (IV) (NCT05930223)
- 19 Apr 2023 Phase-II clinical trials in Lafora disease (In adolescents, In adults) in Italy (IV) (EudraCT2023-000185-34)
- 02 Jun 2020 Valerion Therapeutics terminates a phase I/II trial in Glycogen storage disease type II in USA and United Kingdom, due to lack of funding (NCT02898753) (EudraCT2016-004578-16)